Treatment of cryptococcal meningitis in resource limited settings

Current Opinion in Infectious Diseases

Volumn 22, Issue 5, 2009, Pages 455-463

  Sloan, Derek J ^a,b   Dedicoat, Martin J ^c   Lalloo, David G ^d  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

^c UNIVERSITY OF LIMPOPO   (South Africa)

^d LIVERPOOL SCHOOL OF TROPICAL MEDICINE   (United Kingdom)

Author keywords

Antiretroviral therapy; Cryptococcal meningitis; HIV; Immune reconstitution disease; Resource limited setting

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTIRETROVIRUS AGENT; BACTERIAL ANTIGEN; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; NEVIRAPINE; RECOMBINANT GAMMA INTERFERON;

CLINICAL TRIAL; CRYPTOCOCCAL MENINGITIS; DEVELOPING COUNTRY; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG MEGADOSE; FUNGICIDAL ACTIVITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; INTRACRANIAL PRESSURE; LIVER TOXICITY; LOW DRUG DOSE; MONOTHERAPY; MORBIDITY; MORTALITY; NONHUMAN; OPPORTUNISTIC INFECTION; PROPHYLAXIS; REVIEW; SURVIVAL; TREATMENT OUTCOME; VIROTHERAPY;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; AMPHOTERICIN B; ANTIFUNGAL AGENTS; DEVELOPING COUNTRIES; FLUCONAZOLE; HIV INFECTIONS; HUMANS; MENINGITIS, CRYPTOCOCCAL;

EID: 70249093302     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0b013e32832fa214     Document Type: Review

References (85)

1. Jarvis JN, Harrison TS. HIV-associated cryptococcal meningitis. AIDS 2007; 21:2119-2129.
2. Kisenge PR, Hawkins AT, Maro VP, etal. LowCD4 count plus coma predicts cryptococcal meningitis in Tanzania. BMC Infect Dis 2007; 7:39.
3. Mirza SA, Phelan M, Rimland D, et al. The changing epidemiology of cryptococcosis: an update from population-based active surveillance in 2 large metropolitan areas, 1992-2000. Clin Infect Dis 2003; 36:789-794.
4. Bisson GP, Lukes J,Thakur R, etal. Cryptococcusand lymphocytic meningitis in Botswana. S Afr Med J 2008; 98:724-725.
5. Nissapatorn V. Lessons learned about opportunistic infections in southeast Asia. Southeast Asian J Trop Med Public Health 2008; 39:625-641.
6. Kumar S, Wanchu A, Chakrabarti A, et al. Cryptococcal meningitis in HIV infected: experience from a North Indian tertiary center. Neurol India 2008; 56:444-449.
7. Corbett EL, Churchyard GJ, Charalambos S, etal. Morbidity and mortality in South African gold miners: impact of untreated disease due to human immunodeficiency virus. Clin Infect Dis 2002; 34:1251-1258.
8. French N, Gray K, Watera C, etal. Cryptococcal infection in a cohort of HIV-1-infected Ugandan adults. AIDS 2002; 16:1031-1038.
9. Leimann BC, Koifman RJ. Cryptococcal meningitis in Rio de Janeiro State, Brazil, 1994-2004. Cad Saude Publica 2008; 24:2582-2592.
10. ParkBJ, Wannemuehler KA, Marston BJ, etal. Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. AIDS 2009; 23:525-530.
11. Trachtenberg JD, Kambugu AD, McKellar M, etal. The medical management of central nervous system infections in Uganda and the potential impact of an algorithm-based approach to improve outcomes. Int J Infect Dis 2007; 11:524-530.
12. Charlier C, Dromer F, Leveque C, et al. Cryptococcal neuroradiological lesions correlate with severity during cryptococcal meningoencephalitis in HIV-positive patients in the HAART era. PLoS ONE 2008; 3:e1950.
13. Makombe SD, Nkhata A, Schouten EJ, et al. Burden of cryptococcal meningitis in Malawi. Trop Doct 2009; 39:32-34.
14. Harling G, Orrell C, Wood R. Healthcare utilization of patients accessing an African national treatment program. BMC Health Serv Res 2007; 7:80.
15. van der Horst CM, Saag MS, Cloud GA, et al. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. N Engl J Med 1997; 337:15-21.
16. Bicanic T, Meintjes G, Wood R, et al. Fungal burden, early fungicidal activity, and outcome in cryptococcal meningitis in antiretroviral-naive or antiretroviral-experienced patients treated with amphotericin B or fluconazole. Clin Infect Dis 2007; 45:76-80.
17. Bicanic T, Wood R, Meintjes G, et al. High-dose amphotericin B with flucytosine for the treatment of cryptococcal meningitis in HIV-infected patients: a randomized trial. Clin Infect Dis 2008; 47:123-130.
18. Pitisuttithum P, Tansuphasawadikul S, Simpson AJ, et al. A prospective study of AIDS-associated cryptococcal meningitis in Thailand treated with high-dose amphotericin B. J Infect 2001; 43:226-233.
19. Lortholary O, Poizat G, Zeller V, et al. Long-term outcome of AIDS-associated cryptococcosis in the era of combination antiretroviral therapy. AIDS 2006; 20:2183-2191.
20. Antinori S, Ridolfo A, Fasan M, et al. AIDS-associated cryptococcosis: a comparison of epidemiology, clinical features and outcome in the pre and post-HAART eras. Experience of a single centre in Italy. HIV Med 2009; 10:6-11.
21. Kambugu A, Meya DB, Rhein J, et al. Outcomes of cryptococcal meningitis in Uganda before and after the availability of highly active antiretroviral therapy. Clin Infect Dis 2008; 46:1694-1701.
22. Saag MS, Graybill RJ, Larsen RA, et al. Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin Infect Dis 2000; 30:710-718.
23. Guidelines for the prevention, diagnosis and management of cryptococcal meningitis and disseminated cryptococcosis in HIV-infected patients. S Afr J HIV Med 2007; 28: 25-35.
24. Bicanic T, Wood R, Bekker LG, et al. Antiretroviral roll-out, antifungal roll-back: access to treatment for cryptococcal meningitis. Lancet Infect Dis 2005; 5:530-531.
25. Schaars CF, Meintjes GA, Morroni C, et al. Outcome of AIDS-associated cryptococcal meningitis initially treated with 200mg/day or 400mg/day of fluconazole. BMC Infect Dis 2006; 6:118.
26. Tansuphaswadikul S, Maek-a-Nantawat W, Phonrat B, et al. Comparison of one week with two week regimens of amphotericin B both followed by fluconazole in the treatment of cryptococcal meningitis among AIDS patients. J Med Assoc Thai 2006; 89:1677-1685.
27. Techapornroong M, Suankratay C. Alternate-day versus once-daily administration of amphotericin B in the treatment of cryptococcal meningitis: a randomized controlled trial. Scand J Infect Dis 2007; 39:896-901.
28. Brouwer AE, Rajanuwong A, Chierakul W, et al. Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial. Lancet 2004; 363:1764-1767.
29. Brouwer AE, van Kan HJ, Johnson E, et al. Oral versus intravenous flucytosine in patients with human immunodeficiency virus-associated cryptococcal meningitis. Antimicrob Agents Chemother 2007; 51:1038-1042.
30. Longley N, Muzoora C, Taseera K, et al. Dose response effect of high-dose fluconazole for HIV-associated cryptococcal meningitis in southwestern Uganda. Clin Infect Dis 2008; 47:1556-1561.
31. Dammert P, Bustamante B, Ticona E, et al. Treatment of cryptococcal meningitis in Peruvian AIDS patients using amphotericin B and fluconazole. J Infect 2008; 57:260-265.
32. Bisson GP, Nthobatsong R, Thakur R, et al. The use of HAART is associated with decreased risk of death during initial treatment of cryptococcal meningitisin adults in Botswana. J Acquir Immune Defic Syndr 2008; 49:227-229.
33. Pappas PG, Chetchotisakd P, Larsen RA, et al. AT A Phase II Randomized Trial of Amphotericin B Alone or Combined with Fluconazole in the Treatment of HIV-Associated Cryptococcal Meningitis. Clin Infect Dis 2009 Clin Infect Dis 2009; 48:1775-1883
34. Saag MS, Powderly WG, Cloud GA, et al. Comparison of amphotericin Bwith fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group. N Engl J Med 1992; 326:83-89.
35. Mayanja-Kizza H, Oishi K, Mitarai S, et al. Combination therapy with fluconazole and flucytosine for cryptococcal meningitis in Ugandan patients with AIDS. Clin Infect Dis 1998; 26:1362-1366.
36. Mwaba P, Mwansa J, Chintu C, et al. Clinical presentation, natural history, and cumulative death rates of 230 adults with primary cryptococcal meningitis in Zambian AIDS patients treated under local conditions. Postgrad Med J 2001; 77:769-773.
37. Dromer F, Mathoulin-Pelissier S, Launay O, et al. Determinants of disease presentation and outcome during cryptococcosis: the CryptoA/D study. PLoS Med 2007; 4:e21.
38. Bicanic T, Harrison T, Niepieklo A, et al. Symptomatic relapse of HIV-associated cryptococcal meningitis after initial fluconazole monotherapy: the role of fluconazole resistance and immune reconstitution. Clin Infect Dis 2006; 43:1069-1073.
39. Bii CC, Makimura K, Abe S, et al. Antifungal drug susceptibility of Crypto-coccus neoformans from clinical sources in Nairobi, Kenya. Mycoses 2007; 50:25-30.
40. Hamill RJ. Free fluconazole for cryptococcal meningitis: too little of a good thing? Clin Infect Dis 2006; 43:1074-1076.
41. Guidelines for the prevention, diagnosis and management of cryptococcal meningitis in HIV-infected patients. S Afr J HIV Med 2007. [Epub ahead of print]
42. Ministry of Health: management of HIV-related diseases. Lilongwe, Malawi Ministry of Health 2008. [Epub ahead of print]
43. Milefchik E, Leal MA, Haubrich R, et al. Fluconazole alone or combined with flucytosine for the treatment of AIDS-associated cryptococcal meningitis. Med Mycol 2008; 46:393-395.
44. Dromer F, Bernede-Bauduin C, Guillemot D, et al. Major role for amphotericin B-flucytosine combination in severe cryptococcosis. PLoS ONE 2008;3:e2870.
45. Saag MS, Cloud GA, Graybill JR, et al. A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis. National Institute of Allergy and Infectious Diseases Mycoses Study Group. Clin Infect Dis 1999; 28:291 -296.
46. Jarvis JN, Dromer F, Harrison TS, et al. Managing cryptococcosis in the immunocompromised host. Curr Opin Infect Dis 2008; 21:596-603.
47. Pasqualotto AC. Amphotericin B: the higher the dose, the higher the toxicity. Clin Infect Dis 2008; 47:1110; author reply 1110-1111.
48. Mueller Y, Nguimfack A, Cavailler P, et al. Safety and effectiveness of amphotericin B deoxycholate for the treatment of visceral leishmaniasis in Uganda. Ann Trop Med Parasitol 2008; 102:11-19.
49. Leenders AC, Reiss P, Portegies P, et al. Liposomal amphotericin B (AmBi-some) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis. AIDS 1997; 11:1463-1471.
50. Powderly WG. Editorial commentary: dosing amphotericin B in cryptococcal meningitis. Clin Infect Dis 2008; 47:131 -132.
51. Pappas PG, Bustamante B, Ticona E, et al. Recombinant interferon- gamma 1b as adjunctive therapy for AIDS-related acute cryptococcal meningitis. J Infect Dis 2004; 189:2185-2191.
52. Bozzette SA, Larsen RA, Chiu J, et al. A placebo-controlled trial of maintenance therapy with fluconazole after treatment of cryptococcal meningitis in the acquired immunodeficiency syndrome. California Collaborative Treatment Group. N Engl J Med 1991; 324:580-584.
53. Vibhagool A, Sungkanuparph S, Mootsikapun P, et al. Discontinuation of secondary prophylaxis for cryptococcal meningitis in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy: a prospective, multicenter, randomized study. Clin Infect Dis 2003; 36:1329-1331.
54. Seddon J, Mangeya N, Miller RF, et al. Recurrence of cryptococcal meningitis in HIV-infected patients following immune reconstitution. Int J STD AIDS 2009; 20:274-275.
55. Collett G, Parrish A. Fluconazole donation and outcomes assessment in cryptococcal meningitis. S Afr Med J 2007; 97:175-176.
56. Chang LW, Phipps WT, Kennedy GE, et al. Antifungal interventions for the primary prevention of cryptococcal disease in adults with HIV. Cochrane Database Syst Rev 2005:CD004773.
57. Apisarnthanarak A, Mundy LM. The impact of primary prophylaxis for cryptococcosis on fluconazole resistance in Candida species. J Acquir Immune Defic Syndr 2008; 47:644-645.
58. Parkes-Ratanshi R, Kamali A, Wakeham K, et al. Successful Primary Prevention of Cryptococcal Disease Using Fluconazole Prophylaxis in HIV-infected Ugandan adults In 16th Conference of Retroviruses and Opportunistic Infections; Montreal 2009. www.retroconference.org/2009/Abstracts/ 33938.htm. [Accessed 24 May 2009]
59. Essential prevention and care interventions for adults and adolescents living with HIV in resource-limited settings on World Wide Web URL: http://www.who.int/hiv/pub/prev-care/OMS-EPP-AFF-en.pdf.
60. Micol R, Lortholary O, Sar B, et al. Prevalence, determinants of positivity, and clinical utility of cryptococcal antigenemia in Cambodian HIV-infected patients. J Acquir Immune Defic Syndr 2007; 45:555-559.
61. Liechty CA, Solberg P, Were W, et al. Asymptomatic serum cryptococcal antigenemia and early mortality during antiretroviral therapy in rural Uganda. Trop Med Int Health 2007; 12:929-935.
62. Driver JA, Saunders CA, Heinze-Lacey B, et al. Cryptococcal pneumonia in AIDS: is cryptococcal meningitis preceded by clinically recognizable pneumonia? J Acquir Immune Defic Syndr Hum Retrovirol 1995; 9: 168-171.
63. Wong ML, Back P, Candy G, et al. Cryptococcal pneumonia in African miners at autopsy. Int J Tuberc Lung Dis 2007; 11:528-533.
64. Jarvis JN, Lawn SD, Vogt M, et al. Screening for cryptococcal antigenemia in patients accessing an antiretroviral treatment program in South Africa. Clin Infect Dis 2009; 48:856-862.
65. Graybill JR, Sobel J, Saag M, et al. Diagnosis and management of increased intracranial pressure in patients with AIDS and cryptococcal meningitis. The NIAID Mycoses Study Group and AIDS Cooperative Treatment Groups. Clin Infect Dis 2000; 30:47-54.
66. Bicanic T, Brouwer AE, Meintjes G, et al. Relationship of cerebrospinal fluid pressure, fungal burden and outcome in patients with cryptococcal meningitis undergoing serial lumbar punctures. AIDS 2009; 23:701-706.
67. Manosuthi W, Sungkanuparph S, Chottanapund S, et al. Temporary external lumbar drainage for reducing elevated intracranial pressure in HIV-infected patients with cryptococcal meningitis. Int J STD AIDS 2008; 19:268-271.
68. Woodworth GF, McGirt MJ, Williams MA, et al. The use of ventriculoper-itoneal shunts for uncontrollable intracranial hypertension without ventriculo-megally secondary to HIV-associated cryptococcal meningitis. Surg Neurol 2005; 63:529-531; discussion 522-531.
69. Lortholary O, Fontanet A, Memain N, et al. Incidence and risk factors of immune reconstitution inflammatory syndrome complicating HIV-associated cryptococcosis in France. AIDS 2005; 19:1043-1049.
70. Lawn SD, Harries AD, Anglaret X, et al. Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS 2008; 22:1897-1908.
71. Grant P, Zolopa A. Initiation of antiretroviral therapy in the hospitalized patient with an acute AIDS-related opportunistic infection and other conditions: no time to lose. Curr HIV/AIDS Rep 2009; 6:63-67.
72. Manosuthi W, Chottanapund S, Sungkanuparph S. Mortality rate of early versus deferred initiation of antiretroviral therapy in HIV-1-infected patients with cryptococcal meningitis. J Acquir Immune Defic Syndr 2008; 48:508-509.
73. Makadzange A, Ndhlovu C, Takarinda K, et al. Early vs. delayed ART in the treatment of cryptococcal meningitis in Africa. In 16th Conference of Retroviruses and Opportunistic Infections; Montreal: 2009. www.retroconference. org/2009/Abstracts/36611.htm. [Accessed 28 May 2009]
74. Manosuthi W, Athichathanabadi C, Uttayamakul S, et al. Plasma nevirapine levels, adverse events and efficacy of antiretroviral therapy among HIV-infected patients concurrently receiving nevirapine-based antiretroviral therapy and fluconazole. BMC Infect Dis 2007; 7:14.
75. Wakeham K, Parkes R, Watson V, et al. Co-adminstration of fluconazole increases nevirapine concentrations in HIV infected Ugandans. In 16th Conference on Retroviruses and Opportunistic infections; Montreal: 2009 www.retroconference.org/2009/Abstracts/34543.htm [Accessed 28 May 2009].
76. Tan DB, Yong YK, Tan HY, et al. Immunological profiles of immune restoration disease presenting as mycobacterial lymphadenitis and cryptococcal meningitis. HIV Med 2008; 9:307-316.
77. Murdoch DM, Venter WD, Feldman C, et al. Incidence and risk factors for the immune reconstitution inflammatory syndrome in HIV patients in South Africa: a prospective study. AIDS 2008; 22:601 -610.
78. Klotz SA, Aziz Mohammed A, Girmai Woldemichael M, et al. Immune reconstitution inflammatory syndrome in a resource-poor setting. J Int Assoc Physicians AIDS Care (Chic Ill) 2009; 8:122-127.
79. Lawn SD, Bekker LG, Myer L, et al. Cryptococcocal immune reconstitution disease: a major cause of early mortality in a South African antiretroviral programme. AIDS 2005; 19:2050-2052.
80. French MA. HIV/AIDS: immune reconstitution inflammatory syndrome: a reappraisal. Clin Infect Dis 2009; 48:101-107.
81. Sungkanuparph S, Jongwutiwes U, Kiertiburanakul S. Timing of cryptococcal immune reconstitution inflammatory syndrome after antiretroviral therapy in patients with AIDS and cryptococcal meningitis. J Acquir Immune Defic Syndr 2007; 45:595-596.
82. Bicanic T, Meintjes G, Rebe K, et al. Immune reconstitution inflammatory syndrome in HIV-associated cryptococcal meningitis: a prospective study. J Acquir Immune Defic Syndr 2009; 51:130-134.
83. Khurana RN, Javaheri M, Rao N. Ophthalmic manifestations of immune reconstitution inflammatory syndrome associated with Cryptococcus neofor-mans. Ocul Immunol Inflamm 2008; 16:185-190.
84. Haddow LJ, Sahid F, Moosa MY. Cryptococcal breast abscess in an HIV-positive patient: arguments for reviewing the definition of immune reconstitution inflammatory syndrome. J Infect 2008; 57:82-84.
85. Leal AL, Faganello J, Fuentefria AM, et al. Epidemiological profile of crypto-coccal meningitis patients in Rio Grande do Sul, Brazil. Mycopathologia 2008; 166:71-75.